BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 13, 2015
 |  BioCentury  |  Finance

Cash for new class

$120M B round allows antibiotic play Nabriva to dictate timing of IPO

With antibiotics back in focus for investors, Nabriva Therapeutics AG attracted a handful of U.S. crossover investors for a $120 million series B round that should not only fund the antibiotic company through to commercialization, but also give it the option of going public in the near term.

On April 7, Nabriva raised $50 million in the first tranche of the $120 million round led by new investors Vivo Capital and OrbiMed. New investors EcoR1 Capital and Boxer Capital of Tavistock Life Sciences also participated. So did existing investors HBM Partners, Phase4 Partners, The Wellcome Trust, Global Life Science Ventures and Novartis...

Read the full 501 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >